secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-061514
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica Q3 net loss $4.6M; Auxora reduces hospital days 53% in AIPT trial
-----------------------------------------------------------------------------

- Net loss of $4.6M ($0.82/share) for Q3; cash $14.6M expected to fund through Q3 2024.
- Auxora Phase 1/2 CRSPA in AIPT: 53% reduction in hospital days, 40% ICU days, eliminated TPN vs 27 days historical control. Data at ASH Dec 2023.
- Phase 2b CARPO in acute pancreatitis with SIRS enrolling internationally; topline data H1 2024.
- Preparing IND for Auxora in acute kidney injury; Phase 2 could start H1 2024 subject to funding.
- Operating expenses $4.8M Q3; nine-month net loss $30.2M includes one-time merger charges.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/0000950170-23-061514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000095017023061514/calc-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-061514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer